secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001104659-24-041568
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics reports $86.9M net loss; prioritizes CT-0525, cuts workforce 37%
--------------------------------------------------------------------------------

- Cash of $77.6M as of Dec 31, 2023, expected to fund operations into Q3 2025 after restructuring.
- R&D expenses were $74.1M in 2023 (up from $56.6M); net loss $86.9M vs $61.2M in 2022.
- Prioritizing CT-0525 (anti-HER2 CAR-Monocyte); ceasing new enrollment in CT-0508 study; pausing CT-1119.
- Workforce reduction of ~37% in Q2 2024 as part of pipeline reprioritization and cost savings.
- Appointed John Hohneker, M.D. to board, effective April 1, 2024; Chidozie Ugwumba resigned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924041568/0001104659-24-041568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924041568/tm2410111d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-041568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer